AUTHOR=Khan Nazeer Hussain , Mir Maria , Ngowi Ebenezeri Erasto , Zafar Ujala , Khakwani Muhammad Mahtab Aslam Khan , Khattak Saadullah , Zhai Yuan-Kun , Jiang En-She , Zheng Meng , Duan Shao-Feng , Wei Jian-She , Wu Dong-Dong , Ji Xin-Ying TITLE=Nanomedicine: A Promising Way to Manage Alzheimer’s Disease JOURNAL=Frontiers in Bioengineering and Biotechnology VOLUME=9 YEAR=2021 URL=https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2021.630055 DOI=10.3389/fbioe.2021.630055 ISSN=2296-4185 ABSTRACT=

Alzheimer’s disease (AD) is a devastating disease of the aging population characterized by the progressive and slow brain decay due to the formation of extracellular plaques in the hippocampus. AD cells encompass tangles of twisted strands of aggregated microtubule binding proteins surrounded by plaques. Delivering corresponding drugs in the brain to deal with these clinical pathologies, we face a naturally built strong, protective barrier between circulating blood and brain cells called the blood–brain barrier (BBB). Nanomedicines provide state-of-the-art alternative approaches to overcome the challenges in drug transport across the BBB. The current review presents the advances in the roles of nanomedicines in both the diagnosis and treatment of AD. We intend to provide an overview of how nanotechnology has revolutionized the approaches used to manage AD and highlight the current key bottlenecks and future perspective in this field. Furthermore, the emerging nanomedicines for managing brain diseases like AD could promote the booming growth of research and their clinical availability.